Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma

BACKGROUND: Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin and the safety of olaratumab alone and in combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Villalobos, Victor M., Mo, Gary, Agulnik, Mark, Pollack, Seth M., Rushing, Daniel A., Singh, Arun, Van Tine, Brian A., McNaughton, Rhian, Decker, Rodney L., Zhang, Wei, Shahir, Ashwin, Cronier, Damien M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997100/
https://www.ncbi.nlm.nih.gov/pubmed/31821732
http://dx.doi.org/10.1002/cam4.2728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997100/
https://www.ncbi.nlm.nih.gov/pubmed/31821732
http://dx.doi.org/10.1002/cam4.2728

Ejemplares similares